NORTHWEST BIOTHERAPEUTICS, INC. (OTCMKTS:NWBO) Files An 8-K Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure.
In response to a question received by Northwest Biotherapeutics,
Inc. (the Company) from a shareholder relating to the status of
the Companys Phase III clinical trials, the Company provided the
response set forth in Exhibit 99.1 hereto.
The information in this Item 7.01, including the exhibit attached
hereto, is furnished solely to Item 7.01 of Form 8-K.
Consequently, such information is not deemed filed for the
purposes of Section 18 of the Securities Exchange Act of 1934, or
otherwise subject to the liabilities of that section. Further,
the information in this Item 7.01, including the exhibit, shall
not be deemed to be incorporated by reference into the filings of
the registrant under the Securities Act of 1933.
Item 9.01. Financial Statements and Exhibits.
| (d) | List of Exhibits |
| Exhibit No. | Description |
| Exhibit 99.1 | Response. |
About NORTHWEST BIOTHERAPEUTICS, INC. (OTCMKTS:NWBO)
Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing immunotherapy products to treat cancer. One of the product lines (DCVax-L) is designed to cover all solid tumor cancers in which the tumors can be surgically removed. Another product line (DCVax-Direct) is designed for all solid tumor cancers. The Company’s lead product, DCVax-L, is in an ongoing Phase III trial for diagnosed Glioblastome multiforme (GBM), with over 60 trial sites. Its second product, DCVax-Direct, is being studied in a 60-patient Phase I/II trial for all types of inoperable solid tumors. The 40-patient Phase I stage of the trial has been completed. The Company is working on preparations for Phase II trials of DCVax-Direct. The Company’s platform technology, DCVax, uses activated dendritic cells to mobilize a patient’s own immune system, including T cells, B cells and antibodies and natural killer cells, among others to attack cancer cells to attack their cancer. NORTHWEST BIOTHERAPEUTICS, INC. (OTCMKTS:NWBO) Recent Trading Information
NORTHWEST BIOTHERAPEUTICS, INC. (OTCMKTS:NWBO) closed its last trading session up +0.012 at 0.400 with 427,298 shares trading hands.